Respiratory

The Patient-Centered Outcomes Research Institute (PCORI) has approved an award for the American Academy of Family Physicians (AAFP) of $31 million to fund a large comparative study of asthma treatments.

The specialty drug pipeline includes first- and next-in- class drugs across the oncology and immunology spaces.

Patience and antimicrobial stewardship are the keys to treating sinusitis

The increases had no impact on the efficacy of the drug and were rarely associated with symptoms or sequelae.

Epic research suggests that like COVID-19, flu and other viral pneumonias can result in long-term symptoms like fatigue and brain fog. Why that might be is open question.

Medical groups praise decision, but e-cigarette maker could return to U.S. market.

Proposal follows announced ban on menthol cigarettes, flavored cigars, and e-cig ban could be coming.

Six are currently on the market and more are in the pipeline.

New options are being developed for conditions including psoriatic arthritis, ulcerative colitis, and asthma.

The pipeline includes next-in-class treatments for melanoma, NSCLC, breast cancer, and multiple myeloma.

Real-world study conducted in Japan shows Dupixent (dupilumab) reduced the number of annual severe asthma exacerbations by 53%, there were also adverse events associated with high eosinophil levels in patients who had switched from a different biologic before starting Dupixent.

Data suggest a smartphone application can boost physical activity and relieve symptoms of chronic obstructive pulmonary disease.

Xolair (omalizumab), Fasenra (benralizumab), Dupixent (dupilumab) and Nucala (mepolizumab) can now be self-administered.

Pharmacists are essential for managing complex CF regimens, monitoring their effectiveness, and improving adherence.

This year’s theme is focused on raising awareness about current gaps in care.

E-cigarettes may be helpful for smoking cessation.

Keeping OTC products near the pharmacy counter creates an opportunity for patient counseling and education.

Allergic asthma can be a complicated and confusing diagnosis.

Patients seeking OTC remedies for asthma should be counseled on the risks associated with OTC asthma products.

Tezepelumab is the first biologic medication to show a reduction in severe asthma symptoms.

Pharmacists can offer OTC recommendations for symptom relief.

Pharmacists must be familiar with the different thermometers so they can ensure proper use by the consumer.

The vaccine is indicated to prevent invasive disease and pneumonia caused by 20 Streptococcus pneumoniae serotypes.

New data from a phase 3 clinical trial demonstrated promising results for tezepelumab in adults and adolescents with severe asthma.

Asthma attacks among Hispanic/Latinx adults decreased significantly.